8-K: Xencor Reports Q1 2026 Results, Pipeline Advances

Xencor announced first quarter 2026 financial results, highlighting progress in its oncology and autoimmune pipelines with key data presentations and study initiations planned for the second half of 2026.

Summary

• Xencor reported financial results for the first quarter ended March 31, 2026.
• The company is advancing its wholly-owned clinical pipeline in oncology and autoimmune diseases.
• Key pipeline updates include planned presentations of XmAb819 data in 2H26 to support a pivotal study in 2027, and the initiation of a first-in-human study for XmAb412 in 3Q26.
• The XENITH-UC study for XmAb942 in ulcerative colitis is on track for a blinded interim analysis around year-end 2026 and primary endpoint analysis in 2H27.
• Financial results showed revenue of $4.5 million for Q1 2026, a decrease from $32.7 million in Q1 2025, impacted by a $6.6 million reduction due to royalties on disputed sales.
• Research and development expenses increased to $64.7 million in Q1 2026 from $58.6 million in Q1 2025.
• Net loss attributable to Xencor was $128.9 million ($1.71 per share) in Q1 2026, compared to a net loss of $48.4 million ($0.66 per share) in Q1 2025.
• The company expects to end 2026 with $380-$400 million in cash and sufficient resources to fund operations into mid-2028.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report; while pipeline progress is positive, the significant drop in revenue and widening net loss are concerning.

Positives

• Significant progress in both oncology and autoimmune disease pipelines.
• Expansion cohort data from XmAb819 Phase 1 study for ccRCC to be presented in 2H26, supporting a pivotal study initiation in 2027.
• First-in-human study of XmAb412 (TL1A x IL23p19) on track for 3Q26 start.
• XmAb942 (Xtend anti-TL1A) Phase 2b study in ulcerative colitis is progressing with enrollment expectations supporting a blinded interim analysis around year-end 2026.
• XmAb942 demonstrated a terminal half-life of 74 days supporting a 12-week dosing interval.
• Plamotamab and XmAb657 autoimmune studies are on track for 2H26 progress updates.
• Company expects to end 2026 with $380-$400 million in cash, providing runway into mid-2028.

Negatives

• Revenue for Q1 2026 was $4.5 million, a significant decrease from $32.7 million in Q1 2025.
• Q1 2026 revenue includes a $6.6 million reduction due to royalties on disputed U.S. sales from Alexion.
• Net loss attributable to Xencor was $128.9 million ($1.71 per share) in Q1 2026, a substantial increase from $48.4 million ($0.66 per share) in Q1 2025.
• Other expense, net, increased significantly to $50.8 million in Q1 2026 from $5.1 million in Q1 2025, primarily due to unrealized losses on an equity security.

Risks

• The process of discovering, developing, manufacturing, and commercializing drugs is subject to significant risks.
• Preliminary clinical trial data may not support continued development or regulatory approval.
• Risk of loss of key members of management.
• The fair value of marketable equity securities may decline.
• Risks associated with the timing of events and regulatory approvals.
• Potential for delays in clinical trial initiations or data readouts.
• Uncertainty regarding the outcome of disputed royalty sales.

Future Outlook

Xencor expects to end 2026 with between $380 million and $400 million in cash, cash equivalents and marketable debt securities, and to have sufficient cash resources to fund research and development programs and operations into mid-2028. Key pipeline milestones include presenting XmAb819 data in 2H26, initiating XmAb412 study in 3Q26, and providing updates on Plamotamab and XmAb657 in 2H26.

Management Comments

• Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease.
• We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for the treatment of advanced clear cell renal cell carcinoma at a medical meeting in the second half of 2026, which will help support the initiation of our first pivotal study planned for 2027.
• Our TL1A pipeline continues to advance with strong enrollment in the global Phase 2b XENITH-UC Study of XmAb942 in ulcerative colitis supported by investigator enthusiasm for its potential best-in-class profile in moderately to severely active ulcerative colitis.
• We expect to complete a blinded interim analysis around year-end 2026 and complete the primary endpoint analysis for the study's 12-week induction period during the second half of 2027.
• We also look forward to initiating the first-in-human study of XmAb412, our novel TL1A x IL23p19 bispecific antibody, in the third quarter of 2026.

Industry Context

StockSavvy.ai notes that Xencor's focus on developing engineered antibodies for oncology and autoimmune diseases aligns with major trends in biopharmaceutical innovation, particularly in the areas of bispecific antibodies and targeted therapies. The company's progress in advancing multiple candidates through clinical trials, despite a challenging revenue quarter, demonstrates a commitment to its pipeline development.

Legal Proceedings

• Disputed U.S. sales related to royalties from Alexion.

Stakeholder Impact

• Shareholders may be concerned by the significant increase in net loss and decrease in revenue.
• Employees may be impacted by the company's financial performance and cash runway projections.
• Partners and collaborators will be monitoring the progress of pipeline candidates.
• Creditors may review the company's cash position and future funding plans.

Next Steps

• Present XmAb819 expansion cohort data at a medical conference in 2H26.
• Initiate a pivotal study for XmAb819 in 2027.
• Initiate a sub-study for XmAb819 in treatment-naïve ccRCC patients in 3Q26.
• Present XmAb541 Phase 1 dose-escalation data in 2H26.
• Evaluate plans for a pivotal study of XmAb541 during 2027.
• Initiate a new clinical study combining XmAb541 and XmAb808.
• Complete a blinded interim analysis for the XENITH-UC study of XmAb942 around year-end 2026.
• Complete the primary endpoint analysis for the XENITH-UC study's 12-week induction period in 2H27.
• Initiate the first-in-human study of XmAb412 in 3Q26.
• Provide an update on Plamotamab Phase 1b study progress in 2H26.
• Provide an update on XmAb657 Phase 1 study progress in 2H26.

Key Dates

Recommendation

While pipeline advancements are positive, the significant decline in revenue and widening net loss warrant a cautious approach. The company's cash runway provides some comfort, but the financial performance in Q1 2026 suggests a 'hold' rating until revenue trends improve or pipeline successes translate into more substantial financial gains.

Keywords

Xencor, XNCR, biopharmaceutical, clinical-stage, antibody, oncology, autoimmune diseases, Q1 2026 results